Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nimotuzumab + paclitaxel
- Development stage
- Phase 3
- Lead developer
- Biotech Pharmaceutical Corp
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of nimotuzumab, a humanized anti-EGFR monoclonal antibody, and paclitaxel, a taxane chemotherapy agent. The regimen is primarily used in the treatment of advanced esophageal squamous cell carcinoma (ESCC), with studies showing promising efficacy and acceptable safety profiles. Nimotuzumab targets the epidermal growth factor receptor, which is commonly overexpressed in ESCC and associated with poor prognosis, while paclitaxel works by disrupting microtubule function during cell division.
02
Targets
EGFR (Epidermal growth factor receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nimotuzumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nimotuzumab + paclitaxel.